The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 11: 1580 - 1585

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.11.019

Medical Examination and Clinical Diagnosis

The combined detection of S100β， IL-6 and hs CRP significantly improves the sensitivity of acute TBI diagnosis

  • Xiaogai NIE ,
  • Chuanmei PENG ,
  • Yunfang ZHANG ,
  • Kun TU ,
  • Jiao. WANG
Expand
  • *.Department of Medical Laboratory，Yan'an Hospital of Kunming，Kunming 650051，China

Received date: 2023-12-25

  Online published: 2024-06-13

Fold

Abstract

Objective Through the combined detection method， we tried to find more sensitive biomarkers for the diagnosis of acute TBI， which might provide the exact diagnosis， treatment and monitoring indicators for the clinic. Methods A total of 156 patients with acute TBI admitted to the Emergency Traumatic Center of Yan'an Hospital of Kunming from October 2022 to June 2023 were collected and included the normal and fracture control groups. Peripheral blood samples of the enrolled patients were collected and monitored， S100β and IL-6 were tested and clinical data such as hs-CRP was collected immediately upon admission， then statistical analysisanalysis was conducted. Results Peripheral blood in patients with acute TBI， The levels of S100β， IL-6 and hs-CRP significantly increased， and the area under the ROC curve for diagnosing acute TBI was 0.944， 0.915， and 0.897. The combined detection of the three indicators showed an area under the ROC curve of up to 0.975. Person correlation analysis found a positive correlation between the three indicators， especially S100β with IL-6， The correlation coefficient between them is 0.715. Binary logistic regression analysis found that S100β， IL-6 and hs-CRP are independent risk factors for acute TBI. Conclusions The combined detection of S100β， IL-6 and hs-CRP can effectively improve the sensitivity of acute TBI diagnosis. The mutual promotion of S100β and IL-6 may aggravate the secondary craniocerebral injury caused by inflammatory mechanism， and early targeted treatment may improve the prognosis.

Key words： traumatic brain injury; inflammation; S100β; interleukin-6

Cite this article

Xiaogai NIE , Chuanmei PENG , Yunfang ZHANG , Kun TU , Jiao. WANG . The combined detection of S100β， IL-6 and hs CRP significantly improves the sensitivity of acute TBI diagnosis[J]. The Journal of Practical Medicine, 2024 , 40(11) : 1580 -1585 . DOI: 10.3969/j.issn.1006-5725.2024.11.019

References

1 DEWAN M C， RATTANI A， GUPTA S， et al. Estimating the global incidence of traumatic brain injury［J］. J Neurosurg， 2018，130（4）：1080-1097. doi:10.3171/2017.10.jns17352
2 CAPIZZI A， WOO J， VERDUZCO-GUTIERREZ M. Traumatic Brain Injury： An Overview of Epidemiology， Pathophysiology， and Medical Management［J］. Med Clin North Am， 2020，104（2）：213-238. doi:10.1016/j.mcna.2019.11.001
3 赵清辉，罗秋丽，琚芳迪，等. 创伤性脑损伤中神经炎症相关细胞的研究进展［J］. 生物技术进展， 2020，10（1）：23-29.
4 郑锐哲，毛旻韬，杨西涛，等. 辅酶Q10通过抑制炎症损伤及细胞凋亡保护创伤性颅脑损伤［J］. 实用医学杂志， 2021，37（4）：446-450. doi:10.3969/j.issn.1006-5725.2021.04.006
5 ZHANG X， HUANG X， HANG D， et al. Targeting pyroptosis with nanoparticles to alleviate neuroinflammatory for preventing secondary damage following traumatic brain injury［J］. Sci Adv. 2024，10（2）：eadj4260. doi:10.1126/sciadv.adj4260
6 BOUVIER D， ORIS C， BRAILOVA M， et al. Interest of blood biomarkers to predict lesions in medical imaging in the context of mild traumatic brain injury［J］. Clin Biochem， 2020，85：5-11. doi:10.1016/j.clinbiochem.2020.08.001
7 SAPIN V， GAULMIN R， AUBIN R， et al. Blood biomarkers of mild traumatic brain injury： State of art［J］. Neurochirurgie，2021，67（3）：249-254. doi:10.1016/j.neuchi.2021.01.001
8 张丰，倪海滨，吕汪洄，等. 血清神经元特异性烯醇化酶与白细胞介素-6水平在颅脑损伤相关性脑死亡诊断中的临床意义［J］. 中国急救医学， 2020，40（12）：1157-1162. doi:10.3969/j.issn.1002-1949.2020.12.008
9 王英，廖英.血清S100B、IL-1β、IL-6水平与颅脑损伤患者损伤程度和预后的相关性研究［J］. 川北医学院学报， 2021，36（10）：1352-1354，1394. doi:10.3969/j.issn.1005-3697.2021.10.020
10 SEIDENFADEN S C， KJERULFF J L， JUUL N，et al. Diagnostic accuracy of prehospital serum S100B and GFAP in patients with mild traumatic brain injury： a prospective observational multicenter cohort study - "the PreTBI I study"［J］. Scand J Trauma Resusc Emerg Med， 2021，29（1）：75. doi:10.1186/s13049-021-00891-5
11 SCARBORO M， MCQUILLAN K A. Traumatic Brain Injury Update［J］. AACN Adv Crit Care， 2021，32（1）：29-50. doi:10.4037/aacnacc2021331
12 WANG K K， YANG Z， ZHU T， et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury［J］. Expert Rev Mol Diagn， 2018，18（2）：165-180. doi:10.1080/14737159.2018.1428089
13 TSITSIPANIS C， MILIARAKI M， PAFLIOTI E， et al.Inflammation biomarkers IL-6 and IL-10 may improve the diagnostic and prognostic accuracy of currently authorized traumatic brain injury tools［J］. Exp Ther Med， 2023， 26（2）：364. doi:10.3892/etm.2023.12063
14 杨井金，曹仁贤，文芳. RAGE介导S100蛋白的细胞外信号效应［J］. 国际病理科学与临床杂志， 2009，29（5）：456-460.
15 LE SAGE N， TARDIF P A， FRENETTE J， et al. Detection of S-100β Protein in Plasma and Urine After a Mild Traumatic Brain Injury［J］. Can J Neurol Sci， 2019，46（5）：599-602. doi:10.1017/cjn.2019.61
16 THELIN E P， NELSON D W， BELLANDER B M. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury［J］. Acta Neurochir （Wien）， 2017，159（2）：209-225. doi:10.1007/s00701-016-3046-3
17 FAISAL M， VEDIN T， EDELHAMRE M， et al. Diagnostic performance of biomarker S100B and guideline adherence in routine care of mild head trauma［J］. Scand J Trauma Resusc Emerg Med， 2023，31（1）：3. doi:10.1186/s13049-022-01062-w
18 UCIECHOWSKI P， DEMPKE WCM. Interleukin-6： A Masterplayer in the Cytokine Network［J］. Oncology， 2020，98（3）：131-137. doi:10.1159/000505099
19 CIRYAM P， GERZANICH V， SIMARD J M. Interleukin-6 in Traumatic Brain Injury： A Janus-Faced Player in Damage and Repair ［J］. J Neurotrauma， 2023，40（21-22）：2249-2269. doi:10.1089/neu.2023.0135
20 MOUTACHAKKIR M， LAMRANI HANCHI A， BARAOU A，et al. Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein［J］. Ann Biol Clin （Paris）. 2017，75（2）：225-229. doi:10.1684/abc.2017.1232
21 LIU Y， YANG P， LIU H C， et al. The Significance of The Detection of Serum Lactate Dehydrogenase， Hypersensitive C-Reactive Protein， and N-Terminal Pro-Brain Natriuretic Peptide for the Evaluation of the Severity and Progression of Pediatric Patients with Traumatic Brain Injury［J］. Curr Neurovasc Res， 2022，19（2）：219-224. doi:10.2174/1567202619666220713110941
22 HOSSEININEJAD S M， BOZORGI F， JAHANIAN F， et al. C-Reactive Protein and D-dimer as Prognostic Markers for Clinical Outcomes in Patients with Mild Traumatic Brain Injury： A Cross-Sectional Study［J］. Bull Emerg Trauma， 2023，11（3）：119-124.
23 XU L B， YUE J K， KORLEY F， et al. High-Sensitivity C-Reactive Protein is a Prognostic Biomarker of Six-Month Disability after Traumatic Brain Injury： Results from the TRACK-TBI Study［J］. J Neurotrauma， 2021，38（7）：918-927.
24 ZAR?BA-KOZIO? M， BURDUKIEWICZ M， WYS?OUCH-CIESZY?SKA A. Intracellular Protein S-Nitrosylation-A Cells Response to Extracellular S100B and RAGE Receptor［J］. Biomolecules， 2022，12（5）：613. doi:10.3390/biom12050613
Options
Outlines

/

〈 〉